- Home
- RARE vs ALKT Comparison
RARE vs ALKT Comparison
Compare RARE & ALKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RARE | ALKT |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | RARE | ALKT |
|---|---|---|
| Price | $16.03 | $13.95 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 21 | 8 |
| Target Price | ★ $25.35 | $16.40 |
| AVG Volume (30 Days) | ★ 3.3M | 2.4M |
| Earning Date | 11-03-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $673,000,000.00 | $152,159,000.00 |
| Revenue This Year | $12.70 | $19.73 |
| Revenue Next Year | $29.06 | $14.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 20.13 | ★ 35.68 |
| 52 Week Low | $12.73 | $12.10 |
| 52 Week High | $39.89 | $24.47 |
Technical Indicators
Market Signals| Indicator | RARE | ALKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.08 | 45.90 |
| Support Level | $14.11 | $13.71 |
| Resistance Level | $17.67 | $14.52 |
| Average True Range (ATR) | 0.90 | 0.67 |
| MACD | 0.03 | 0.11 |
| Stochastic Oscillator | 37.06 | 50.41 |
Price Performance
Historical ComparisonAbout RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.
About ALKT Alkami Technology Inc.
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.